Leading the Way in Liver Disease CONSULTING
Expert Hepatology Consulting by Melissa Palmer, MD, FAASLD
Discover unparalleled expertise in liver disease consulting with Melissa Palmer, MD, an internationally recognized leader in Hepatology for > 35 years.
I handle all consultations personally and provide rapid turnaround time, regardless of time zone.
Contact Melissa Palmer, MD FAASLD at
drpalmer@liverdisease.com
UPCOMING ONLINE AASLD SEMINAR TO BE PRESENTED BY
MELISSA PALMER, MD ON 1/15/26
GLP-1 RAs and Hepatotoxicity
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have revolutionized the management of T2DM and obesity. While these agents are generally well-tolerated, rare instances of hepatotoxicity, including liver tests elevations, cholestatic hepatitis, acute liver injury and auto-immune-like hepatitis have been reported, in some cases contributing to discontinuation of further clinical development. This is counterintuitive as many GLP-1RA have demonstrated hepatoprotective effects, which is underscored by the recent approval of semaglutide for patients with MASH and fibrosis. Many others ( either as single, bi or tri agonists) are in advanced stages of clinical development for MASH and or obesity.
Please join me on January 15, 2026 at 11 AM Eastern Time for this online AASLD seminar on the topic of GLP-1RA and Hepatotoxicity.
Registration is now open via the link below.
https://aasld.zoom.us/meeting/register/ilm543sSRTqClknqp2rjZw
I have niche expertise in Drug-Induced Liver Injury (DILI), also known as Hepatotoxicity, occurring during clinical development.
My DILI expertise extends to drugs for all diseases (not just liver diseases). Here are just some of the ways that I can support your company in DILI assessment :
1. Evaluate preclinical program for potential hepatotoxicity
2. Assist with eligibility criteria related to liver tests (ALT,AST,TBIL,ALP,GGT)
3. Assist with criteria for enhanced monitoring, pausing and stopping specific to your investigational product and clinical evaluation to date
4. Assist with minimal data set of causality assessment
5. Real-time adjudication of suspected cases
6. Formation of and chairing adjudication committee
7. Regulatory preparation and interaction
Here are some of my recent publications related to liver safety:
1. Palmer M, et al. The Impact of COVID-19 and COVID-19 Vaccination on Detection, Assessment, and Management of Suspected Acute Drug-Induced Liver Injury Occurring during Clinical Trials: Consensus Recommendations from the IQ DILI Initiative. Drug Saf. 2025 Aug 5. doi: 10.1007/s40264-025-01591-0. Online ahead of print. PMID: 40762948 Review.
Meet Melissa Palmer, MD
Melissa Palmer, MD, moderator of the AASLD 2025 session– “Rechallenge after Drug-Induced Liver Injury: A Debate of the Merits and Hazards from Industry, the FDA and Clinical Academia”
My Liver Disease Training
Dr. Melissa Palmer is an internationally acclaimed hepatologist known for her groundbreaking work in liver disease. She holds a BA from Columbia University ( 1980) and a medical degree from the Mount Sinai School of Medicine in New York City where she also completed her liver fellowship (1989).
In addition to her near 100 peer-reviewed hepatology-related publications, Dr. Palmer is the author of the best-selling book “Dr. Melissa Palmer’s Guide to Hepatitis & Liver Disease (Penguin Putnam 2004)”.
Some of my recent publications:
1. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022 May;7(5):388-390. doi: 10.1016/S2468-1253(22)00062-0. Epub 2022 Mar 3. PMID: 35248211
My Professional Experience in Hepatology
2019-present
Chief Executive Officer
Liver Consulting LLC
2020 – 2022
Chief Medical Officer
Gannex Pharma, a wholly owned company of Ascletis Pharma
Jan 2019-Aug 2019
Head of Liver Disease
Takeda Pharmaceuticals
Managed a team, pre-clinical through clinical, in liver disease.
2015-2019
Chair, Liver Safety Committee
Global Development Lead, Hepatology
Shire Pharmaceuticals
Managed the development of Shire’s portfolio of liver disease drugs including volixibat an ASBT inhibitor. Inaugurated Shire’s first liver safety committee. Acquired by Takeda.
2013-2015
Chair, Liver Safety Committee
Global Head of Hepatology
Senior Vice-President of Clinical Research
Senior Vice President of Pharmacovigilance
Kadmon Pharmaceuticals
Managed the development of Kadmon’s liver disease drugs and led clinical team of both drug developers and safety physicians. Acquired by Sanofi.
2009-2019
Clinical Professor of Hepatology
NYU Langone
Provided teaching and expertise on liver disease
2009-2011
Director of Hepatology
NYU Langone Hepatology Associates
Plainview, NY
Acquired by NYU Langone. Ran the largest solo hepatology medical practice in the United States
Jan 1991-Dec 2009
Self-employed,
Melissa Palmer, MD
Plainview, NY
Solo medical practice devoted to care and treatment of individuals with liver disease.
My Specialized Services
Comprehensive Liver Disease Consulting
Offering expert advice to Industry on all types of liver conditions, including personalized treatment strategies and management plans specific to your investigational product, strategic plans and executive management vision
Innovative Trial Design Consulting
Designing cutting-edge clinical trials for liver diseases, ensuring regulatory compliance, safety and optimal study outcomes.
Regulatory and Advisory Services
Providing regulatory consulting and forming advisory boards to guide pharmaceutical developments in hepatology.
Data Safety Monitoring and Due Diligence
Conducting thorough safety monitoring and due diligence assessments to ensure the efficacy and safety of liver disease drugs, as well as drugs for all other diseases.
Reach Out for Expert Liver Consulting
Connect with Melissa Palmer, MD today to explore how her liver disease expertise can help your company’s liver programs succeed